These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8018965)

  • 21. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
    Harbeck N; Untch M; Pache L; Eiermann W
    Br J Cancer; 1994 Mar; 69(3):566-71. PubMed ID: 7510120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective evaluation of prognostic factors in operable breast cancer.
    Hawkins RA; Tesdale AL; Killen ME; Jack WJ; Chetty U; Dixon JM; Hulme MJ; Prescott RJ; McIntyre MA; Miller WR
    Br J Cancer; 1996 Nov; 74(9):1469-78. PubMed ID: 8912547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CA 15-3 (Mucin-1) and physiological characteristics of breast cancer from Lahore, Pakistan.
    Begum M; Karim S; Malik A; Khurshid R; Asif M; Salim A; Nagra SA; Zaheer A; Iqbal Z; Abuzenadah AM; Alqahtani MH; Rasool M
    Asian Pac J Cancer Prev; 2012; 13(10):5257-61. PubMed ID: 23244146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer].
    Schönborn I; Minguillon C; Lichtenegger W; Zschiesche W; Spitzer E
    Geburtshilfe Frauenheilkd; 1995 Oct; 55(10):566-71. PubMed ID: 8543129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status.
    Sacks NP; Smith K; Norman AP; Greenall M; LeJeune S; Harris AL
    Eur J Cancer; 1993; 29A(3):426-8. PubMed ID: 8398346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of epidermal growth factor receptor in node-positive breast cancer.
    Grimaux M; Romain S; Remvikos Y; Martin PM; Magdelénat H
    Breast Cancer Res Treat; 1989 Oct; 14(1):77-90. PubMed ID: 2690971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Invasive micropapillary carcinoma of the breast: high incidence of lymph node metastasis with extranodal extension and its immunohistochemical profile compared with invasive ductal carcinoma.
    Zekioglu O; Erhan Y; Ciris M; Bayramoglu H; Ozdemir N
    Histopathology; 2004 Jan; 44(1):18-23. PubMed ID: 14717664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer.
    Muir IM; Reed RG; Stacker SA; Alexander AI; McKenzie IF; Bennett RC
    Br J Cancer; 1991 Jul; 64(1):124-7. PubMed ID: 1854611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer.
    Newby JC; A'Hern RP; Leek RD; Smith IE; Harris AL; Dowsett M
    Br J Cancer; 1995 Jun; 71(6):1237-42. PubMed ID: 7779717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
    Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
    Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.
    Gee JM; Robertson JF; Ellis IO; Willsher P; McClelland RA; Hoyle HB; Kyme SR; Finlay P; Blamey RW; Nicholson RI
    Int J Cancer; 1994 Dec; 59(5):619-28. PubMed ID: 7960234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of an immunoenzymatic assay for determining estrogen and progesterone receptors in breast tumors].
    Kopczyński Z; Stachowicz A; Kociałkowski K; Grodecka-Gazdecka S; Faryńska E
    Ginekol Pol; 1992; 63(10):528-33. PubMed ID: 1305562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
    Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
    Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A simplified immuno-enzymetric assay of the epidermal growth factor receptor in breast tumors: evaluation in 282 cases.
    Grimaux M; Mady E; Remvikos Y; Laine-Bidron C; Magdelenat H
    Int J Cancer; 1990 Feb; 45(2):255-62. PubMed ID: 2406203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.